Cinnarizine Tables:

Pharmacokinetics

Bioavailability Peak plasma level Plasma half-life Active metabolites Elimination
high variability not established 2 to 3 hours 4 to 6 hours not established predominantly extrarenal
Probably polymorphically determined "debrisoquine" metabolism. The pharmacokinetics of cinnarizine in humans is only incompletely documented.

Dose
Indication Administration
Initial loading dose
Dose Interval
Maintenance dose
Dose* Interval
motion sickness oral 12.5 to 25 mg** 8 to 12 hours - -
labyrinthine vertigo oral 25 mg 8 to 24 hours 25 mg 8 to 24 hours
*Considering the possible side-effects, a long-term administration is not advisable; high doses (more than 75 mg/day) should be avoided in particular.
**The first dose should be taken one or two hours before traveling.

Copyright © 1996 Infomed-Verlags AG